期刊文献+

探讨脑钠肽在急性肺栓塞近期预后评价中的价值

Exploring Value of Brain Natriuretic Peptide in Evaluating Short-term Prognosis of Acute Pulmonary Embolism
在线阅读 下载PDF
导出
摘要 目的探讨血清脑钠肽(BNP)在急性肺栓塞(APE)近期预后评价中的价值。方法选择APE并行外周血BNP检查的84例患者,按照BNP水平,分为BNP升高组41例与BNP正常组43例。比较两组患者住院期间不良事件发生率(肺动脉高压、右心功能不全、心源性休克、死亡)。通过ROC曲线分析BNP对APE不良预后的诊断价值及确定最佳临界值。结果两组肺动脉高压及右心功能不全发生率经统计学处理差异有统计学意义。两组心源性休克发生率及死亡率经统计学处理差异无统计学意义。BNP诊断APE不良预后的ROC曲线下面积为0.829,最佳临界值为93.15 pg/m L(敏感度:69.0%,特异度:92.3%)。结论 APE患者BNP升高时,近期预后不佳。BNP对APE不良预后有很好的诊断价值。 Objective to explore value of serum brain natriuretic peptide(BNP) in short-term prognosis of acute pulmonary embolism(APE). Methods choose 84 cases APE patients with peripheral blood BNP examination, according to BNP level, divide them into BNP elevation group(41 cases) and BNP normal group(43 cases). Compare adverse events incidence(pulmonary hypertension, right heart insufficiency, cardiogenic shock, and death) of two groups during hospitalization. Analyze diagnostic value of BNP for APE poor prognosis and determine the best critical value with ROC curve. Results incidence difference of pulmonary hypertension and right ventricular dysfunction was statistically significant between two groups. Cardiogenic shock incidence and mortality showed no significant difference between two groups. Area under ROC curve of BNP diagnosed APE poor prognosis was 0.829, the best critical value was 93.15 pg/m L(sensitivity: 69%, specificity: 92.3%). Conclusion short-term prognosis is no good when increasing BNP of APE patients, and BNP has good diagnostic value for APE poor prognosis.
作者 张艳敏 付萌 庞桂芬 ZHANG Yan-min;FU Meng;PANG Gui-fen(Chengde Medical College Affiliated Hospital,Chengde,Hebei,06700)
出处 《智慧健康》 2018年第21期125-126,共2页 Smart Healthcare
关键词 肺栓塞 脑钠肽 预后 Pulmonary embolism Brain natriuretic peptide Prognosis
  • 相关文献

参考文献3

二级参考文献74

  • 1荆志成,邓可武.急性肺动脉血栓栓塞症的溶栓治疗[J].中华医学杂志,2004,84(22):1932-1934. 被引量:20
  • 2邹治鹏,何建国,程显声,赵彦芬,陈白屏,高莹,熊长明,倪新海,荆志诚.230例急性肺动脉血栓栓塞症患者对症治疗、抗凝治疗和溶栓治疗的住院转归[J].中国循环杂志,2006,21(3):219-221. 被引量:27
  • 3Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatnlent of major pulmonary embolism. Ann Thorae Surg, 2004,77:819-823.
  • 4Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev, 2005, 19 : 179-202.
  • 5PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d' Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005,112:416-422.
  • 6Karmy-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients : an AAST multicenter study. J Trauma, 2007,62 : 17-24.
  • 7Barral FG. Vena cava filters: why, when, what and how? J Cardiovasc Surg (Torino) , 2008,49:35-49.
  • 8Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism : a European nmlticenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol, 1992, 19:239-245.
  • 9Dalla-Volta S, Palla A, Santolicandro A, et al. PALMS 2: aheplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol, 1992, 20:520-526.
  • 10Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990, 98: 1473-1479.

共引文献417

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部